Group 1 - The core viewpoint of the article highlights that Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and currently trading at 4.27 HKD with a transaction volume of 10.87 million HKD [1] - Zhaoke Ophthalmology has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals, a leading pharmaceutical company in Indonesia, for its core product, atropine sulfate eye drops (NVK002), aimed at slowing the progression of myopia in children and adolescents [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia, which includes an upfront payment and potential milestone payments based on certain achievements [1] Group 2 - Earlier this year, Zhaoke Ophthalmology's new drug application for a 0.01% dosage of atropine sulfate eye drops and a 0.02% dosage has been accepted by the National Medical Products Administration of China and is currently under review [1]
港股异动 兆科眼科-B(06622)再涨超7% 公司与PT Ferron达成战略合作 推动核心产品在印尼商业化